Ocular Therapeutix Inc (OCUL)
Healthcare
Biotechnology
8.20 $
-3.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Ocular Therapeutix Inc (OCUL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.2% of the shares are freely tradable; institutional investors hold 95.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
95.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
14.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
219Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.91 | 32,653,764 | +2.7 | 03/31/2026 |
| Deep Track Capital, LP | 8.99 | 19,686,282 | +143.9 | 03/31/2026 |
| BlackRock Inc | 7.37 | 16,132,931 | +3.4 | 03/31/2026 |
| venBio Select Advisor LLC | 5.62 | 12,315,000 | +14.3 | 03/31/2026 |
| SUMMER ROAD LLC | 5.43 | 11,879,825 | +6.9 | 03/31/2026 |
| VR Adviser, LLC | 4.73 | 10,346,926 | +41.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.98 | 8,719,039 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 6.00 | 13,134,074 | +0.8 | 05/31/2026 |
| Fidelity Growth Company Fund | 4.44 | 9,716,358 | +0.7 | 05/31/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 3.02 | 6,619,445 | +0.5 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.